Cargando…
Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice
BACKGROUND: Viral replication as well as an immunopathological component are assumed to be involved in the development of coxsackie B virus (CBV)-induced myocarditis. We observed that mycophenolic acid (MPA), the active metabolite of the immunosuppressive agent mycophenolate mofetil (MMF), inhibits...
Autores principales: | Padalko, Elizaveta, Verbeken, Erik, Matthys, Patrick, Aerts, Joeri L, De Clercq, Erik, Neyts, Johan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC317291/ https://www.ncbi.nlm.nih.gov/pubmed/14687413 http://dx.doi.org/10.1186/1471-2180-3-25 |
Ejemplares similares
-
Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus
por: Allaoui, Abire, et al.
Publicado: (2022) -
Mycophenolate mofetil in the treatment of lupus nephritis
por: Yong, Patrick FK, et al.
Publicado: (2008) -
Comparative Efficacy and Safety of Mycophenolate Mofetil and Azathioprine in Combination with Corticosteroids in the Treatment of Lymphocytic Myocarditis
por: Blagova, Olga, et al.
Publicado: (2023) -
Comparison of Renal Responses Between Continuous Mycophenolate Mofetil and Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Lupus Nephritis
por: Liao, Yu-Wan, et al.
Publicado: (2022) -
Severe Enteropathy From Mycophenolate Mofetil
por: Jehangir, Asad, et al.
Publicado: (2016)